The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.30
Bid: 2.00
Ask: 2.30
Change: -0.015 (-0.69%)
Spread: 0.30 (15.00%)
Open: 2.30
High: 2.50
Low: 2.21
Prev. Close: 2.165
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Company Secretary Change

7 Oct 2022 16:44

RNS Number : 2369C
Immupharma PLC
07 October 2022
 

07 October 2022

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Appointment of Company Secretary

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm the appointment of Ward Williams Limited as Company Secretary to the Company. The appointment is with immediate effect.

 

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

 

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

 

 

+44 (0) 203 368 3550

 

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

About Ward Williams LimitedWard Williams is a leading provider of quality business support and personal financial services. They differentiate themselves through the range of services provided. Their client-focused services are delivered through two divisions: Chartered Accountants and HR Consultants, all working together from four locations in Weybridge, Uxbridge, Sunninghill and London. For more information go to: https://www.wardwilliams.co.uk/about-us/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
COSUPGGCUUPPGAM
Date   Source Headline
2nd Nov 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
16th Oct 20173:29 pmRNSHolding(s) in Company
4th Oct 20177:00 amRNSCompletion of Lanstead Sharing Agreement
27th Sep 20177:00 amRNSInterim Results
26th Sep 20177:00 amRNSPreparation of Lupuzor'sT Regulatory Submissions
21st Sep 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
19th Sep 20177:00 amRNSNotification of Interim Results
18th Aug 20175:09 pmRNSAIM Rule 17 Notice
12th Jul 201711:00 amRNSGrant of Options
30th Jun 201712:04 pmRNSResult of AGM
30th Jun 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
7th Jun 20177:00 amRNSAnnual Report & Notice of AGM
1st Jun 20177:00 amRNSFinal Results
22nd May 20177:00 amRNSNotification of Full Year Results
17th May 20177:00 amRNSUpdate on Lupuzor Phase III Study
31st Mar 201710:17 amRNSNew Employee Share Option Plan & Grant of Options
31st Mar 20178:33 amRNSNew Employee Share Option Plan & Grant of Options
24th Mar 20177:00 amRNSImmuPharma to present at Master Investor Show
22nd Mar 20178:51 amRNSHolding(s) in Company
20th Mar 201711:41 amRNSHolding(s) in Company
20th Mar 20177:00 amRNSHolding(s) in Company
10th Mar 20173:52 pmRNS£4.1 Million Fund Raise via Accelerated Bookbuild
10th Mar 20177:00 amRNSAccelerated Bookbuild for the Issue of Equity
6th Mar 20173:55 pmRNSHolding(s) in Company
17th Feb 20172:04 pmRNSHolding(s) in Company
25th Jan 20177:00 amRNSUpdate on Lupuzor Phase III Study
24th Jan 20177:00 amRNSChange of Adviser
29th Dec 201610:54 amRNSHolding(s) in Company
22nd Dec 20167:00 amRNSUpdate on Lupuzor Pivotal Phase III Study
16th Nov 20167:00 amRNSUpdate on Cancer Compound IPP-204106 'Nucant'
9th Nov 20167:00 amRNSHolding(s) in Company
26th Oct 20163:42 pmRNSHolding(s) in Company
21st Oct 20165:13 pmRNSClose of Accelerated Bookbuild
21st Oct 20161:33 pmRNSProposed Accelerated Bookbuild for Vendor Placing
30th Sep 20167:00 amRNSHalf-year Report
14th Sep 20167:00 amRNSUPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
7th Sep 20167:00 amRNSUPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
21st Jul 20168:32 amRNSHolding(s) in Company
1st Jul 20163:52 pmRNSHolding(s) in Company
27th Jun 20164:41 pmRNSSecond Price Monitoring Extn
27th Jun 20164:35 pmRNSPrice Monitoring Extension
20th Jun 20167:00 amRNSAppointment of Joint Broker
9th Jun 20165:56 pmRNSHolding(s) in Company
8th Jun 20167:00 amRNSSymposium with Lupuzors Inventor Prof. S Muller
7th Jun 20167:00 amRNSEuropean Patients Commence Dosing in Lupuzor
2nd Jun 20165:26 pmRNSDirector/PDMR Shareholding
31st May 201610:38 amRNSHolding(s) in Company
26th May 20162:00 pmRNSResult of AGM
25th May 20167:00 amRNSHolding(s) in Company
4th May 20167:01 amRNSAnnual Financial Report & Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.